Topline data were announced from a phase 3 trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity.

Emotional eating and body dissatisfaction mediate links between BMI changes and mental health. These psychosocial factors ...

A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI reduction than those receiving placebo, according to top-line results released ...

Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established ... 1981–2019 (61% objectively measured, 39% self-reported, mean age 51.4 years).

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.

Obesity is about much more than just the inconvenience of carrying a few extra pounds. It’s a condition that can harm many areas of a person’s health. And because obesity affects an estimated ...

Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established ... from 1981-2019 (61% objectively measured, 39% self-reported, mean age 51.4 years).